Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.68 USD
-0.09 (-1.89%)
Updated May 2, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 6:00 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VNDA 4.68 -0.09(-1.89%)
Will VNDA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
Other News for VNDA
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Shareholder Capital delivers letter to board of Vanda Pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZĀ® ANDA Litigation